Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 8/20 | 0.54 |
| ▸ | ACE | P12821 | 2/20 | 0.54 |
| ▸ | MMEL1 | Q495T6 | 3/20 | 0.53 |
| ▸ | CTSS | P25774 | 1/20 | 0.53 |
| ▸ | CTSK | P43235 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | APP | P05067 | 1/20 | 0.47 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.47 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12888110 | 1.00 | MME (0.54) | MMEACEMMEL1CTSSCTSK | |
| SCHEMBL1908521 | 1.00 | MME (0.54) | MMEACEMMEL1CTSSCTSK | |
| SCHEMBL597498 | 1.00 | MME (0.54) | MMEACEMMEL1CTSSCTSK | |
| SCHEMBL1231410 | 1.00 | MME (0.54) | MMEACEMMEL1CTSSCTSK | |
| SCHEMBL21572792 | 1.00 | MME (0.54) | MMEACEMMEL1CTSSCTSK | |
| SCHEMBL1232158 | 1.00 | MME (0.54) | MMEACEMMEL1CTSSCTSK | |
| SCHEMBL1231592 | 0.91 | MME (0.56) | MMEACEMMEL1CTSSCTSK | |
| SCHEMBL12888104 | 0.91 | MME (0.56) | MMEACEMMEL1CTSSCTSK | |
| SCHEMBL1231595 | 0.91 | MME (0.56) | MMEACEMMEL1CTSSCTSK | |
| SCHEMBL1231435 | 0.91 | MME (0.56) | MMEACEMMEL1CTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017033128-A1 | BIPHENYL-SUBSTITUED 4-AMINO-BUTYRIC ACID DERIVATIVES AND THEIR USE IN THE SYNTHESIS OF NEP INHIBITORS | NOVARTIS AG (CH) | 2017-03-02 | — | — | WO | disclosed |